HGH Fragment 176-191 — an unmodified 16-amino acid sequence corresponding to residues 176-191 of human growth hormone — has not been studied in humans [1]. This means that a significant portion of what the title of this article suggests, such as established dosing ranges, known pharmacokinetics, or specific cycle lengths, does not actually exist in the published literature for this specific compound. Where the outline of commonly searched questions assumes data that is not present, this article states that directly, rather than filling the gap with numbers drawn from commercial sources or vendors. This article reports solely research parameters and study data appearing in reviewed and regulatory sources scanned for this series. It provides no personal dosing recommendations, reconstitution instructions, or guidance on administration of any kind.
Dosage ranges reported in studies
Based on the sources collected for this series, only one study directly tested the unmodified hGH Fragment 176-191 sequence in a living model. It used a single dose level rather than a range. In this 1978 study, researchers administered synthetic C-terminal fragments of human growth hormone, including hGH 176-191, to normal rats at a dose of 5 nmol/kg body weight. This was given as a single intravenous injection to observe effects on blood glucose and plasma insulin [2].
No published studies identified in this series report a dosing range of „250mcg–500mcg” for humans, nor vial concentrations of 5mg/10mg/6mg, as tested clinical or preclinical dose levels for this specific compound. Such numbers, which are widely circulated in commercial vendor offerings, reflect product packaging and marketing conventions, rather than doses established by published studies. This article does not repeat these numbers as if they were derived from study data, as no such studies exist in the reviewed sources.
Methods of administration documented in studies
Injectable drug. The only identified study of the unmodified fragment used a single intravenous injection in rats [2]. A separate 2022 study used the peptide as a component incorporated into chitosan nanoparticles, at a concentration of 50 nm/ml, alongside doxorubicin. This was part of an experimental anticancer drug delivery system tested in vitro against breast cancer cells. This is a specialized laboratory nanoparticle formulation, not a standalone injection protocol. The study did not test the peptide itself in vivo [3].
Nasal spray formulations. No peer-reviewed studies identified in this series tested an unmodified HGH Fragment 176-191 nasal spray formulation. Nasal spray products associated with this compound name in commercial contexts are not supported by any studies identified herein.
Reconstitution methods. No published studies describe a reconstitution protocol, i.e., mixing lyophilized peptide with a solvent, for the unmodified fragment. This is because no human injection studies or animal self-dosing studies beyond a single 1978 rat experiment have been identified. The „preparation” in the 2022 nanoparticle study was a nanoparticle synthesis process using ionotropic gelation with chitosan and gum arabic—not a reconstitution method relevant for peptide self-administration [3].
Pharmacokinetics: Half-life and duration of action
No pharmacokinetic study identified in this series—that is, no study measuring absorption, distribution, half-life, or clearance—exists for unmodified HGH Fragment 176-191. Specifically, no half-life number (such as „1-2 hours”) for this exact compound was found in the sources compiled here. Any such number seen elsewhere should be treated with caution, as it cannot be traced back to a peer-reviewed pharmacokinetic study of this fragment in the research reviewed for this paper.
For context, full-length hGH itself has been studied pharmacokinetically in other research. This includes studies on its molecular isoforms, such as the 20-kDa and 22-kDa forms, and their differing behaviors in circulation [4], [5]. However, pharmacokinetic data for the full hormone does not transfer to the small C-terminal fragment of it, and no source reviewed here makes this comparison with supporting data.
Study/Trial Duration
The only identified study testing the unmodified fragment directly administered a single acute dose. Effects were measured over the course of this single experiment, rather than through repeated dosing or an extended „cycle” [2].
No multi-week, multi-month, or six-month safety studies of unmodified HGH Fragment 176-191 have been identified in either humans or animals in the sources reviewed for this series. Where data on „cycle length” or study duration actually exist in the broader literature—for instance, in the 14-day chronic studies on mice and 19-day studies on rats of the related compound AOD-9604 discussed in Article 2—such data apply to a structurally distinct compound, not to the unmodified fragment [6], [7].
Reported side effects and safety signals
Adverse events recorded in the literature. The only relevant study found that hGH 176-191, along with several related C-terminal fragments (172-191, 177-191, 178-191), induced transient increases in blood glucose and more sustained increases in plasma insulin in rats after a single dose. At the same dose, hGH fragments containing the 178-191 sequence significantly reduced insulin sensitivity in IVITTs [2]. These findings describe effects on glucose and insulin regulation in rats—not a general side-effect profile in humans—and should not be extrapolated to humans.
Data leaks. No human studies of any kind, no long-term animal studies, and no dedicated safety studies in humans or animals of unmodified HGH Fragment 176-191 exist in the sources reviewed for this series.
A 2026 narrative review on performance-enhancing peptides affecting the growth hormone/IGF-1 axis, which refers to AOD9604 (hGH 176-191) as one compound within a broader unregulated category, notes that adverse effects reported in this general class of compounds include endocrine and metabolic disturbances, fluid retention, musculoskeletal symptoms, and injection site reactions [8]. This reflects the entire class of compounds broadly, derived largely from self-administration reports and pharmacological reasoning of related peptides—rather than confirmed data specific to the unmodified 176-191 fragment [8].
Why is there no standardized approved dosage?
HGH Fragment 176-191 is not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body as a labeled pharmaceutical product.
Approved medications carry standardized, regulator-reviewed dosing information because this information is generated by a formal clinical trial process. This includes dose-finding studies (Phase I), monitoring of efficacy and side effects (Phase II/III), and regulatory review of the resulting data. As no such trial process has occurred for this compound, no standardized, approved dosing exists, and none can be accurately reported. Any „typical dosing” language attributed to this compound in commercial or informal sources reflects a research or vendor convention, not medical guidance, and is not equivalent to approved drug label dosing instructions.
FAQs
What doses were tested in the studies? Only one dose level in one study is documented for the unmodified fragment: 5 nmol/kg body weight, administered as a single intravenous dose in rats [2]. No human dose of any kind has been tested in the published studies identified in this series.
How long do the effects last, according to pharmacokinetic data? It is not possible to answer this because no pharmacokinetic study (measuring half-life or duration of action) of unmodified HGH Fragment 176-191 has been identified in the reviewed sources. The only animal study describes its glucose-raising effect as „short-lived” and its insulin-raising effect as „more sustained,” but it did not report specific half-life numbers [2].
What was the minimum effective dose in the cited studies? The 1978 study tested one dose level (5 nmol/kg), not a dose-response design. Therefore, no minimum effective dose can be identified from it [2]. No other study identified in this series established a dose-response relationship for this compound.
Is there an optimal time to take it, based on research protocols? None of the studies identified in this series report a specific time of day or nutritional status for administering unmodified HGH Fragment 176-191. The only relevant study does not specify fasting or fed conditions in a way that would support a „best time” recommendation [2].
Disclaimer
HGH Fragment 176-191 is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any equivalent regulatory body for human medical use, and no standardized, approved dosage exists for it. Published research identified for this compound is limited to a single animal study from 1978 measuring glucose and insulin effects and a 2022 in vitro study of anti-cancer nanoparticles. No human trials, no dedicated pharmacokinetic studies, and no long-term safety studies of this specific compound have been identified. This article reports solely on what has been published and clearly states where no data exists; it does not provide dosing numbers, reconstitution instructions, or administration guidance for personal use. This content is for general educational and informational purposes only, is not medical advice, and should not be relied upon as the basis for decisions to use, purchase, or administer this or any peptide.
References
[1] Wikipedia contributors. (2025, December 30). HGH Fragment 176–191. Wikipedia, The Free Encyclopedia. https://en.wikipedia.org/wiki/HGH_Fragment_176%E2%80%93191
[2] Ng, F. M., & Bornstein, J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. American Journal of Physiology, 234(5), E521–E526. https://doi.org/10.1152/ajpendo.1978.234.5.E521
Habibullah, M. M., Mohan, S., Syed, N. K., Makeen, H. A., Jamal, Q. M. S., Alothaid, H., Bantun, F., Alhazmi, A., Hakamy, A., Kaabi, Y. A., Samlan, G., Lohani, M., Thangavel, N., & Al-Kasim, M. A. (2022). Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Design, Development and Therapy, 16, 1963–1974. https://doi.org/10.2147/DDDT.S367586
[4] Hashimoto, Y., Kamioka, T., Hosaka, M., Mabuchi, K., Mizuchi, A., Shimazaki, Y., Tsunoo, M., & Tanaka, T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. The Journal of Clinical Endocrinology & Metabolism, 85(2), 601–606. https://doi.org/10.1210/jcem.85.2.6377
Baumann, G., MacCart, J. G., & Amburn, K. (1983). The molecular nature of circulating growth hormone in normal and acromegalic man: Evidence for a principal and minor monomeric forms. The Journal of Clinical Endocrinology & Metabolism, 56(5), 946–952. https://doi.org/10.1210/jcem-56-5-946
Heffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., & Ng, F. M. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189. https://doi.org/10.1210/endo.142.12.8522
[7] Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278. https://doi.org/10.1159/000053183
[8] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, 1822475. https://doi.org/10.3389/fendo.2026.1822475